ArticleNeuro-oncology advances
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03561207 (3D-PREDICT REGISTRY), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- In vitro assays as a tool to personalize treatment in central nervous system tumors: a systematic literature review.Clinical and experimental medicine · 2026Pooled it
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.Neuro-oncology · 2026Article
- Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors.Pituitary · 2026Article
- Review
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
- Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.Advanced drug delivery reviews · 2026Review
- Rapid Functional Drug Screening of Passage-Zero Patient Brain Tumor Tissues Ex Vivo: Results from a Clinical Feasibility Study.Research square · 2025Article
- Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma.Cancer research communications · 2025Article
- Trends in 4D Printed Shape Memory Biomaterials for Tissue Engineering Applications.Current pharmaceutical design · 2025Review
- Translational Aspects of 3D and 4D Printing and Bioprinting.Advanced healthcare materials · 2024Review
- Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma.Scientific reports · 2024Article
- Functional precision medicine assay for recurrent meningioma: a proof of principle. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Article
- Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.JCO precision oncology · 2024Article
- The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma.FEBS letters · 2024Article
- Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond.Frontiers in oncology · 2024Article
- Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.British journal of cancer · 2023Article
- Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.Cellular and molecular life sciences : CMLS · 2023Article
- Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.Life science alliance · 2022Article
- Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundClinical outcomes in high-grade glioma (HGG) have remained relatively unchanged over the last 3 decades with only modest increases in overall survival. Despite the validation of biomarkers to classify treatment response, most newly diagnosed (ND) patients receive the same treatment regimen. This study aimed to determine whether a prospective functional assay that provides a direct, live tumor cell-based drug response prediction specific for each patient could accurately predict clinical drug response prior to treatment.
methodsA modified 3D cell culture assay was validated to establish baseline parameters including drug concentrations, timing, and reproducibility. Live tumor tissue from HGG patients were tested in the assay to establish response parameters. Clinical correlation was determined between prospective ex vivo response and clinical response in ND HGG patients enrolled in 3D-PREDICT (ClinicalTrials.gov Identifier: NCT03561207). Clinical case studies were examined for relapsed HGG patients enrolled on 3D-PREDICT, prospectively assayed for ex vivo drug response, and monitored for follow-up.
resultsAbsent biomarker stratification, the test accurately predicted clinical response/nonresponse to temozolomide in 17/20 (85%,
conclusionThis study both validates the developed assay analytically and clinically and provides case studies of its implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.